已发表论文

接受中等强度他汀类药物治疗的冠心病患者载脂蛋白E  基因多态性与缺血性卒中的相关性

 

Authors Lv P, Zheng Y, Huang J, Ke J, Zhang H

Received 29 May 2020

Accepted for publication 24 August 2020

Published 23 October 2020 Volume 2020:16 Pages 2459—2466

DOI https://doi.org/10.2147/NDT.S265194

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Yuping Ning

Objective: To study the association of apolipoprotein E (APOE ) gene polymorphism with ischemic stroke (IS) in coronary heart disease (CHD) patients treated with medium-intensity statins.
Methods: The retrospective study was performed on 662 samples including 169 CHD subjects complicated with IS, 296 subjects with CHD, and 197 control subjects. The APOE  gene was obtained from case files. Univariable and multivariable logistic regression analyses were utilized to recognize the possible risks of CHD and IS.
Results: The frequency of ϵ3-ϵ4 genotype was increased in the CHD group (=0.013) and CHD-IS group (=0.001), the frequency of ϵ4 allele was also increased in the CHD group (=0.047) and the CHD-IS group (=0.009) compared with control group. ϵ3-ϵ4 genotype was the independent risk for CHD and CHD-IS after adjusting for traditional risk factors with adjusted odds ratio (AOR) 2.210, 95%CI: 1.263– 3.867, =0.005) and (AOR 2.794, 95%CI: 1.539– 5.072, =0.002). The ϵ4 allele was also significantly associated with CHD (AOR 2.126, 95%CI: 1.265– 3.575,=0.004) and CHD-IS (AOR 2.740, 95%CI: 1.569– 4.784, =0.001).
Conclusion: These results demonstrated that ϵ4 allele influenced the development of CHD with or without IS, especially for the genotype of ϵ3-ϵ4. CHD patients carrying the ϵ3-ϵ4 genotype and the ϵ4 allele were significantly associated with the incidence of IS, even if medium-intensity statins had been used.
Keywords: apolipoprotein E , polymorphism, coronary heart disease, ischemic stroke, statins